Attovia Therapeutics IPO
Attovia Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for autoimmune and inflammatory diseases. The company's pipeline targets unmet medical needs in conditions where current treatments are inadequate or have significant side effects.
Key Facts
| Industry | Biotechnology |
| Funding | Raised $332M in upsized IPO (originally sought $182M-$212.5M); Goldman Sachs-backed; $731.5M valuation |
About Attovia Therapeutics
Attovia Therapeutics operates in the biotechnology sector with a focus on developing innovative treatments for autoimmune and inflammatory diseases. These conditions represent a significant market opportunity, as millions of patients worldwide suffer from diseases where the immune system mistakenly attacks healthy tissue. The company's approach involves developing novel therapeutic candidates designed to modulate immune responses with improved efficacy and safety profiles compared to existing treatments.
The autoimmune and inflammatory disease market is substantial and growing, driven by increasing disease prevalence, improved diagnostics, and demand for more targeted therapies with fewer side effects. Companies in this space compete to develop treatments that can effectively control disease progression while minimizing the immunosuppression and other adverse effects associated with current standard-of-care therapies. Success in this therapeutic area requires strong scientific expertise, robust clinical development capabilities, and the ability to navigate complex regulatory pathways.
IPO Status
Attovia Therapeutics has successfully completed its initial public offering and is now trading publicly on the Nasdaq under the ticker ATTO. The Goldman Sachs-backed biotechnology company upsized its offering to $332 million, significantly exceeding its original target of $182-212.5 million. The upsized IPO values the company at approximately $731.5 million, reflecting strong investor demand for the biotech's immune therapy platform. The company is focused on developing therapies for autoimmune and inflammatory diseases using its proprietary ATTOBODY platform, which has drawn significant interest from sector-dedicated investors. With its lead programs currently in Phase 1 clinical trials, Attovia went public during a favorable window for biotech IPOs in early August 2026, alongside other biotechnology companies like Braveheart Bio and Vogenx. The successful upsizing and completion of the IPO demonstrates strong market confidence in the three-year-old company despite having only early-stage assets in its pipeline.
Competitors
Frequently Asked Questions
Does Attovia Therapeutics have a stock?
No, Attovia Therapeutics has not had an IPO and remains a private company. The company has not publicly filed for an initial public offering with the SEC. Sign up for alerts to stay informed.
When is the Attovia Therapeutics IPO date?
There is no confirmed IPO date for Attovia Therapeutics at this time. The company has not announced plans to go public or filed the necessary paperwork with regulatory authorities. Sign up for alerts to stay informed.
How can I buy Attovia Therapeutics stock?
Attovia Therapeutics stock is not currently available for purchase as the company is privately held. Once the company goes public, shares would be available through traditional brokerage accounts on public exchanges. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts